Sustained Antifungal Activity from a Ketoconazole-Loaded Nanostructured Mesoporous Silicon Platform

Silicon

Volumn 5, Issue 3, 2013, Pages 213-217

  Tang, Lynda ^a   Saharay, Arun ^a   Fleischer, William ^a   Hartman, Philip S ^a   Loni, Armando ^b   Canham, Leigh T ^b   Coffer, Jeffery L ^a  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

^b pSiMedica Ltd   (United Kingdom)

Author keywords

Antifungal compounds; Drug delivery; Nanomaterials; Porous silicon

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DELIVERY; FUNGI; NANOSTRUCTURED MATERIALS; SCANNING ELECTRON MICROSCOPY; TARGETED DRUG DELIVERY; THERMOGRAVIMETRIC ANALYSIS;

ANTI-FUNGAL; ANTI-FUNGAL ACTIVITY; ANTIFUNGAL COMPOUNDS; CANDIDA ALBICANS; EXTENDED DELIVERIES; MESOPOROUS SILICON; NANO-STRUCTURED; NANOSIZED CHANNELS;

POROUS SILICON;

EID: 84880818004     PISSN: 1876990X     EISSN: 18769918     Source Type: Journal    
DOI: 10.1007/s12633-013-9143-5     Document Type: Article

References (17)

1. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP (2008) Mesoporous silicon in drug delivery applications. J Pharm Sci 97: 632-651.
2. Anglin EJ, Cheng L, Freeman WR, Sailor MJ (2008) Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 60: 1266-1277.
3. Canham LT (1997) Properties of porous silicon. Institution of Engineering and Technology Press, London.
4. Sailor MJ (2012) Porous silicon in practice: preparation, characterization and applications. Wiley VCH, Weinheim.
5. Bowditch PK, Waters H, Gale P, Rice E, Scott AM, Canham LT, Reeves CL, Loni A, Cox TI (1999) In vivo assessment of tissue compatibility and calcification of bulk and porous silicon. Mat Res Soc Symp Proc 536: 149-154.
6. Wang M, Coffer JL, Dorraj K, Hartman PS, Loni A, Canham LT (2010) Sustained antibacterial activity from triclosan-loaded nanostructured meoporous silicon. Mol Pharm 7: 2232-2239.
7. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339: 520-532.
8. Monk B, Goggeau A (2008) Outwitting multidrug resistance to antifungals. Science 321: 367-369.
9. Low SP, Williams KA, Canham L, Voelcker NH (2006) Evaluation of mammalian cell adhesion on surface-modified porous silicon. Biomaterials 27: 4538-4546.
10. Alvarez SD, Derfus AM, Schwartz MP, Bhatia SN, Sailor MJ (2009) The compatibility of hepatocytes with chemically modified porous silicon with reference to in vitro biosensors. Biomaterials 30: 26-34.
11. Kashanian S, Harding F, Irani Y, Klebe S, Marshall K, Loni A, Canham L, Fan D, Williams KA, Voelcker NH, Coffer JL (2010) Evaluation of mesoporous silicon/polycaprolactone composites as ophthalmic implants. Acta Biomater 6: 3566-3572.
12. Hosmani AH, Thorat YS (2011) Synthesis and evaluation of nanostructured particles of salt of ketoconazole for solubility enhancement. Digest J Nanomat Biostruct 6: 1411-1418.
13. Duhem N, Rolland J, Riva R, Guillet P, Schumers J-M, Jerome C, Gohy J-F, Prea V (2012) Tocol modified glycol chitosan for the oral delivery of poorly soluble drugs. Int J Pharm 423: 452-460.
14. Taneri F, Güneri T, Aigner Z, Kata M (2002) Improvement in the physicochemical properties of ketoconazole through complexation with cyclodextrin derivatives. J Incl Phenom 44: 257-260.
15. van Speybroeck M, Barillaro V, Thi TD, Mellaerts R, Martens J, van Humbeeck J, Vermant J, Annaert P, van den Mooter G, Augustijns P (2009) Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J Pharm Sci 98: 2648-2658.
16. Silva V, Diaz A, Diaz MC (2004) Antifungal susceptibility of 50 Candida isolates from invasive mycoses in Chile. Med Mycol 42: 283-285.
17. Ramos L, Brignol N, Bakhtiar R, Ray T, McMahon M, Tse F (2000) High throughput approaches to the quantitative analysis of ketoconazole, a potent inhibitor of cytochrome P450 3A3, in human plasma. Rapid Comm Mass Spectrom 14: 2282-2293.